Serum Hepatitis B core-related antigen (HBcrAg) correlates with covalently-closed circular DNA transcriptional activity in chronic hepatitis B patients

The development of novel antiviral agents and immunomodulatory approaches to cure chronic HBV infection requires new biomarkers capable to reflect the intrahepatic activity of the virus and CHB stages and define new meaningful treatment endpoints. Indeed, there is an unmet need for standardized assays able to provide mechanistic insights into the effects of the novel antiviral and immuno-modulatory agents and to assess treatment efficacy[1].

Source: Journal of Hepatology - December 7, 2018 Category: Gastroenterology Authors: Testoni Barbara, Leboss é Fanny, Scholtes Caroline, Berby Françoise, Miaglia Clothilde, Subic Miroslava, Loglio Alessandro, Facchetti Floriana, Lampertico Pietro, Levrero Massimo, Zoulim Fabien Source Type: research